Literature DB >> 9311593

Incidence of invasive cancers following cutaneous malignant melanoma.

F Levi1, C La Vecchia, L Randimbison, V C Te, G Erler.   

Abstract

It has long been suggested that subjects diagnosed with cutaneous malignant melanoma (CMM) have an excess rate of subsequent neoplasms. To provide further quantitative information on the issue, we have considered 1,780 histologically confirmed CMM diagnosed between 1974 and 1994 by the Cancer Registries of the French-speaking Swiss Cantons of Vaud and Neuchatel (760,000 inhabitants) and followed up to the end of 1994 for the occurrence of a second primary. A total of 194 neoplasms was observed vs. 111.7 expected, corresponding to a standardized incidence ratio (SIR) of 1.7 [95% confidence interval (CI) 1.5-2.0]. When skin cancers were excluded, 87 subsequent neoplasms were observed vs. 84.9 expected (SIR 1.0). Significant excess rates were observed for basal cell (SIR 4.4), squamous cell (SIR 3.1) and melanoma (SIR 4.7) of the skin, as well as for prostatic cancer (SIR 2.1). The increased rates of subsequent skin cancer were somewhat larger in males, whereas all the SIRs were systematically greater below age 60. The SIRs of subsequent skin cancer remained above unity for 5 years or longer since diagnosis of CMM, in the absence of a clear pattern in trend with time since diagnosis. The cumulative incidence following CMM was 3% for CMM, 4% for squamous cell and 14% for basal cell carcinoma 20 years after diagnosis of CMM. Our results confirm that patients diagnosed with CMM have excess risks of subsequent melanoma and non-melanomatous skin neoplasms which justify focused prevention and surveillance of skin lesions in these patients. Subjects with CMM do not have any appreciable overall excess of non-skin neoplasms, even after long-term follow-up.

Entities:  

Mesh:

Year:  1997        PMID: 9311593     DOI: 10.1002/(sici)1097-0215(19970904)72:5<776::aid-ijc12>3.0.co;2-7

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Increased risk of second primary cancers after a diagnosis of melanoma.

Authors:  Porcia T Bradford; D Michal Freedman; Alisa M Goldstein; Margaret A Tucker
Journal:  Arch Dermatol       Date:  2010-03

2.  Clinical characteristics of cutaneous melanoma and second primary malignancies in a dutch hospital-based cohort of cutaneous melanoma patients.

Authors:  Haike M J van der Velden; Michelle M van Rossum; Willeke A M Blokx; Jan B M Boezeman; Marie-Jeanne P Gerritsen
Journal:  Dermatol Res Pract       Date:  2009-12-31

3.  Risk of subsequent primary tumor development in melanoma patients.

Authors:  Veronika Tóth; Zsófia Hatvani; Beáta Somlai; Judit Hársing; János F László; Sarolta Kárpáti
Journal:  Pathol Oncol Res       Date:  2013-05-17       Impact factor: 3.201

4.  Risk factors for keratinocyte skin cancer in patients diagnosed with melanoma, a large retrospective study.

Authors:  Pablo Espinosa; Ruth M Pfeiffer; Zaida García-Casado; Celia Requena; Maria Teresa Landi; Rajiv Kumar; Eduardo Nagore
Journal:  Eur J Cancer       Date:  2015-12-17       Impact factor: 9.162

5.  BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.

Authors:  Christian Monnerat; Agnès Chompret; Caroline Kannengiesser; Marie-Françoise Avril; Nicolas Janin; Alain Spatz; Jean-Marc Guinebretière; Catalin Marian; Michel Barrois; Françoise Boitier; Gilbert M Lenoir; Brigitte Bressac-de Paillerets
Journal:  Fam Cancer       Date:  2007-07-12       Impact factor: 2.375

6.  On the roles of solar UV irradiance and smoking on the diagnosis of second cancers after diagnosis of melanoma.

Authors:  William B Grant
Journal:  Dermatoendocrinol       Date:  2012-01-01

7.  Identifying related cancer types based on their incidence among people with multiple cancers.

Authors:  Chris D Bajdik; Zenaida U Abanto; John J Spinelli; Angela Brooks-Wilson; Richard P Gallagher
Journal:  Emerg Themes Epidemiol       Date:  2006-11-08

8.  Site-specific occurrence of nonmelanoma skin cancers in patients with cutaneous melanoma.

Authors:  R E Neale; D Forman; M F G Murphy; D C Whiteman
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.